This clinical trial is focused on studying Prostate Cancer, a condition where cells in the prostate gland grow uncontrollably. The study is investigating a new diagnostic method using a special imaging agent called Copper Cu 64 PSMA I&T. This agent is used in a type of scan known as PET/CT, which helps doctors see if the cancer has spread to the lymph nodes in the pelvis. The purpose of the study is to determine how well this imaging agent can detect the presence or absence of cancer in these lymph nodes in men who have been newly diagnosed with prostate cancer and are planning to undergo surgery to remove the prostate and some surrounding lymph nodes.

Participants in the study will receive an injection of the Copper Cu 64 PSMA I&T solution, which is administered through an intravenous injection. After the injection, a PET/CT scan will be performed to capture detailed images of the pelvic area. The study aims to compare these images with the results from the surgery to see if the scan accurately identifies cancerous lymph nodes. This will help determine the effectiveness of the Copper Cu 64 PSMA I&T scan in staging prostate cancer.

The study will also monitor any side effects that may occur from the time the imaging agent is given until 72 hours afterward. The results of this study could provide valuable information on whether this new scanning method can improve the detection of prostate cancer spread, potentially leading to better treatment planning for patients. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.